Search Results
Your search for The matches 34625 pages
Showing 21501 - 21550Dexamethasone Mouthwash in Preventing Everolimus-Related Stomatitis in Women With Breast Cancer
In the phase II SWISH study reported in The Lancet Oncology, Rugo et al found that use of a dexamethasone-based mouthwash may prevent everolimus-related stomatitis in postmenopausal women receiving everolimus (Afinitor) for hormone receptor–positive, HER2-negative metastatic breast cancer....
Thoracic 2017: SBRT Offers Curative Option for Patients With Lung Cancer Aged 80 and Older
Patients in their 80s and 90s who have early-stage lung cancer but cannot undergo an operation can be treated safely and effectively with stereotactic body radiation therapy (SBRT), according to research presented by Cassidy et al at the 2017 Multidisciplinary Thoracic Cancers Symposium (Abstract...
Thoracic 2017: Updated Data Confirm Benefits of Single-Fraction SBRT for NSCLC
New research led by a radiation oncologist at Roswell Park Cancer Institute indicates that less may be more when it comes to some forms of radiation therapy for cancer. In a presentation highlighted in a plenary session (Abstract 4) at the 2017 Multidisciplinary Thoracic Cancers Symposium in San...
Belgian Study Combines BRAF and MEK Inhibition in Advanced BRAF 600–Mutant Melanoma
In a Belgian two-center phase II trial reported in The Lancet Oncology, Schreuer et al found that rechallenge with the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinist) showed activity in patients with BRAF V600–mutant melanoma whose disease had progressed on...
Adding Temozolomide to Short-Course Radiotherapy in Older Patients With Glioblastoma
In a phase III trial reported in The New England Journal of Medicine, Perry et al found that adding temozolomide to short-course radiotherapy improved overall survival in patients aged ≥ 65 years with newly diagnosed glioblastoma. The survival advantage was largest among patients with methylated ...
Douglas E. Wood, MD, on Lung Cancer Screening
Douglas E. Wood, MD, of the University of Washington, discusses the importance of broad access to and education about lung cancer screening—now approved for people at high risk for the disease—and the need for expanded criteria for screening eligibility.
Charles B. Simone, II, MD, on NSCLC: CTCs as a Biomarker for Early Detection
Charles B. Simone, II, MD, of the University of Maryland Medical Center, discusses results from a large prospective study in locally advanced non–small cell lung cancer, which suggest that circulating tumor cells may be a promising biomarker of progressive or recurrent disease and may help guide...
Boris Sepesi, MD, on NSCLC, TILs, and Overall Survival
Boris Sepesi, MD, of The University of Texas MD Anderson Cancer Center, discusses immune cells within tumors and the potential role for checkpoint inhibitor therapy in the neoadjuvant setting of locally advanced lung cancer (Abstract 7).
Zofia Piotrowska, MD, on NSCLC: Resistance Mechanisms
Zofia Piotrowska, MD, of the Massachusetts General Hospital Cancer Center, discusses heterogeneity and variation in resistance mechanisms among EGFR-mutant non–small cell lung cancer patients with at least one postresistance biopsy (Abstract 1).
Zhongxing Liao, MD, on Proton-Beam Radiotherapy for Locally Advanced Disease
Zhongxing Liao, MD, of The University of Texas MD Anderson Cancer Center, discusses the continued improvement in planning, delivery, and patient selection for proton therapy, which can both reduce radiation exposure and increase tumor dose.
Jennifer Ho, MD, on Thoracic Cancers: Reirradiation With IMPT
Jennifer Ho, MD, of The University of Texas MD Anderson Cancer, discusses study results on the use of intensity-modulated proton therapy, which can provide durable local control with minimal toxicity in patients who can have extended survivals; the data also suggest that higher doses may improve...
Tracey L. Evans, MD, on NSCLC: Combined-Modality Therapy
Tracey L. Evans, MD, of the University of Pennsylvania, discusses the data supporting use of chemotherapy with radiation in locally advanced non–small cell lung cancer, targeted treatments and immunotherapy, and some of the controversies now debated.
Martin J. Edelman, MD, on NSCLC: Final Results of a CALGB Alliance Trial
Martin J. Edelman, MD, of Fox Chase Cancer Center, discusses study findings from a phase III study of celecoxib in addition to standard chemotherapy for advanced non–small cell lung cancer with COX-2 overexpression (Abstract 2).
Maximilian Diehn, MD, PhD, on Liquid Biopsies/Cell-Free DNA: Clinical Uses
Maximilian Diehn, MD, PhD, of Stanford School of Medicine, discusses promising clinical applications of circulating tumor DNA in patients with thoracic malignancies: noninvasive detection of resistance mechanisms to targeted agents and treatment response assessment.
Shraddha M. Dalwadi, MBA, on Stage I NSCLC: Racial Disparities in Treatment and Outcome
Shraddha M. Dalwadi, MBA, MD Candidate in the class of 2017 at Texas A&M Health Science Center, discusses findings from a SEER database study that showed African Americans and American Indians with stage I non–small cell lung cancer were less likely to receive definitive treatment and had lower ...
Richard J. Cassidy III, MD, on NSCLC and SBRT in Older Patients
Richard J. Cassidy III, MD, of Emory Winship Cancer Institute, discusses results from a multicenter analysis of stereotactic body radiotherapy for early-stage non-small cell lung cancer in patients 80 years and older; the patients tolerated the treatment well and had excellent estimated rates of...
Kamran Ahmed, MD, on Lung Cancer, Radiation, and Immune Checkpoint Inhibitors
Kamran Ahmed, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses results from a small study of pneumonitis in patients who received thoracic radiotherapy within 6 months of anti–PD-1 therapy, anti–PD-L1 therapy, anti–CTLA-4 therapy, or some combination of these drugs...
Thoracic 2017: Combination of Radiation and Immune Checkpoint Therapy Holds Potential for Lung Cancer
An emerging approach for cancer treatment seeks to combine radiation therapy with immune checkpoint inhibitors to more effectively control tumors in the chest with an acceptable risk of severe treatment-related side effects. About 10% of patients in a retrospective analysis of metastatic lung...
Thoracic 2017: Racial Disparities Persist in Treatment and Survival of Early-Stage Lung Cancer
Analysis of the largest American cancer database indicates that racial disparities persist in the treatment and outcomes of patients diagnosed with stage I non–small cell lung cancer (NSCLC). Despite increased availability of potentially curative treatments for early-stage NSCLC,...
Thoracic 2017: Proton Therapy Offers New Treatment Possibility for Recurrent Lung Cancer
A new study offers hope for patients with recurrent lung cancer, who historically have been considered ineligible for curative treatment. In the largest analysis to date of reirradiation using intensity-modulated proton therapy for lung and other thoracic tumors, more than three-fourths of patients ...
Common Genetic Variation and Risk of Gallbladder Cancer in India
Several single-nucleotide polymorphisms in the chromosomal region containing both ABCB1 and ABCB4 genes were associated with an increased risk of gallbladder cancer, in an Indian case-control genome-wide association study reported in The Lancet Oncology by Mhatre et al. Study Details The study...
Thoracic 2017: Genetic Profile of Treatment-Resistant Lung Cancer More Variable Than Previously Thought
The genetic mutations underlying treatment resistance in non–small cell lung cancer (NSCLC) are more complex and dynamic than previously thought. Analysis of 355 biopsied tumors from patients who acquired resistance to epidermal growth factor receptor (EGFR) inhibitors, the most common form...
Antisense Oligonucleotide Custirsen Combined With Docetaxel and Prednisone in Metastatic Prostate Cancer
In the phase III SYNERGY trial reported in The Lancet Oncology, Chi et al found that the addition of the second-generation antisense oligonucleotide custirsen to docetaxel and prednisone did not improve overall survival in patients with metastatic castration-resistant prostate cancer. Custirsen...
Thoracic 2017: Biomarker Test Shows Cancer Recurrence Months Before CT Scans
Results from a prospective clinical trial showed that a blood test looking at specific biomarkers was able to detect recurrences of lung cancer an average of 6 months before conventional imaging methods found evidence of recurrence. In the largest prospective clinical trial to date of circulating...
ASCO Statement: President's Budget Will Devastate U.S. Research Enterprise
ASCO President Daniel F. Hayes, MD, FACP, FASCO, released the following statement today: “We soundly oppose President Trump's budget outline, which would cut $6 billion from the National Institutes of Health (NIH). Reducing NIH's funding by nearly 20% will devastate our nation's...
Association of DNA Thioguanine Nucleotide Concentration and Outcome During Maintenance Therapy for Childhood ALL
In a substudy of a European phase III trial (Nordic Society of Pediatric Hematology and Oncology ALL2008) reported in The Lancet Oncology, Nygaard Nielsen et al found that higher leukocyte DNA-incorporated thioguanine nucleotide (DNA-TGN) levels were associated with an improved relapse-free...
SGO 2017: Hospital Readmission Metrics May Not Be an Ideal Measure in Ovarian Cancer Cases
To reduce costs and improve quality of care, the Centers for Medicare & Medicaid Services (CMS) has made reducing hospital readmission rates a priority, yet two research studies presented at the 2017 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer question the use...
SGO 2017: Parental Concern About Lack of Sexual Activity Declining as Reason Not to Vaccinate Children Against HPV
Parental concern that a child is not sexually active is declining as a reason parents do not vaccinate their children against papillomavirus (HPV), according to a study presented by Beavis et al at the Society of Gynecologic Oncology’s (SGO) 2017 Annual Meeting on Women’s Cancer...
SGO 2017: New Immunotherapy Axalimogene Filoslisbac Shows Positive Results in Cervical Cancer
A new immunotherapy drug, axalimogene filoslisbac (AXAL), showed improved survival rates for patients with cervical cancer, according to a study presented at the 2017 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer. Study coauthor Charles Leath, MD, MSPH, an SGO member ...
SGO 2017: Secondary Endpoint Results of Phase III ENGOT-OV16/NOVA Trial of Niraparib in Recurrent Ovarian Cancer
Secondary endpoint results from the phase III ENGOT-OV16/NOVA trial of niraparib were presented at the 2017 Society for Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer, by Sven Mahner, MD, Director, Department of Gynecology and Obstetrics, University of Munich. “The results of...
FDA Approves Pembrolizumab for Relapsed or Refractory Classical Hodgkin Lymphoma in Adult and Pediatric Patients
The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda), an anti–PD-1 (programmed cell death protein 1) therapy, for the treatment of adult and pediatric patients who have refractory classical Hodgkin lymphoma or have relapsed after three or more prior lines of...
Researchers Find Evidence-Based Radiation Treatment After Lumpectomy Leads to High-Quality, High-Value Care
A new study demonstrates that the use of less radiation therapy for patients with breast cancer who have undergone lumpectomy does not negatively impact patient outcomes, and could result in significant reductions in health-care costs. These findings, which examine patient eligibility for...
Busulfan and Melphalan vs Carboplatin, Etoposide, and Melphalan in High-Risk Neuroblastoma
In a phase III trial reported in The Lancet Oncology, Ladenstein et al found that high-dose chemotherapy with busulfan and melphalan vs carboplatin, etoposide, and melphalan was associated with an improved event-free survival in patients with high-risk neuroblastoma and adequate disease response to ...
Factors Associated With Early Death in Childhood Cancer
In a study reported in the Journal of Clinical Oncology, Green et al found that risk factors for death within 1 month of diagnosis of childhood cancer included age up to 1 year, specific diagnoses, and minority race/ethnicity. The study involved analysis of data from SEER (Surveillance,...
Cancer Care Ontario and ASCO Clinical Practice Guideline: Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer
As reported in the Journal of Clinical Oncology by Dhesy-Thind, ofJuravinski Cancer Centre, Hamilton Health Sciences, and colleagues, Cancer Care Ontario and ASCO have issued a clinical practice guideline on the use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer. The...
Benefit of Imatinib in Chronic Myeloid Leukemia Persists Long Term in IRIS Trial
Long-term follow-up of patients with chronic myeloid leukemia (CML) randomized to imatinib in the IRIS trial was reported by Hochhaus et al in The New England Journal of Medicine. In the open-label crossover-design trial, 1,106 patients with CML were randomized to receive imatinib at 400 mg/d (n = ...
European Cohort Study of Vasectomy and Prostate Cancer Risk
In a large European cohort study reported in the Journal of Clinical Oncology, Smith Byrne et al found that vasectomy was not associated with an increased overall risk of prostate cancer or death from prostate cancer but appeared to increase the risk of lower-grade disease. Other studies have...
Binimetinib vs Dacarbazine: Which Was More Effective in NRAS-Mutant Melanoma?
In the phase III NEMO trial reported in The Lancet Oncology, Dummer et al found that treatment with the MEK inhibitor binimetinib improved progression-free survival vs dacarbazine in patients with advanced NRAS-mutant melanoma. Study Details In the open-label trial, 402 patients from 118 sites in ...
Evidence of Stage Shift in Ovarian Cancer Detected in UK Screening Study
As reported in the Journal of Clinical Oncology, Rosenthal et al found evidence of a shift to an earlier stage among ovarian cancers detected in high-risk women in the UK Familial Ovarian Cancer Screening Study. Study Details The study was performed to evaluate performance of screening using...
Blinatumomab vs Chemotherapy in Advanced Acute Lymphoblastic Leukemia
In the phase III TOWER trial reported in The New England Journal of Medicine, Kantarjian et al found that blinatumomab (Blincyto) treatment improved overall survival vs chemotherapy in heavily pretreated patients with B-cell precursor acute lymphoblastic leukemia (ALL). Blinatumomab received...
ASCO Honors Researchers and Scientists for Significant Advancements in Cancer Treatment and Care
ASCO and the Conquer Cancer Foundation of ASCO (CCF) have proudly announced the winners of ASCO's Special Awards, the Society's highest honors, and the CCF Women Who Conquer Cancer Mentorship Award. The recipients of these awards include researchers, patient advocates, and global oncology leaders...
FDA Approves Ribociclib as Initial Therapy for Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer
On March 13, 2017, the U.S. Food and Drug Administration (FDA) approved ribociclib (Kisqali), a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor–positive,...
Preclinical Study Finds SPOP Mutation Drives Prostate Cancer Subtype
A genetically engineered mouse model developed by Blattner et al investigating the role of the gene Speckle Type BTB/POZ Protein, or SPOP, as a driver of prostate cancer has found that the mutation drives prostate neoplasia through coordinate deregulation of both P13K/mTOR and androgen receptor...
ACC.17: History of Exercise Helps Prevent Heart Disease After Breast Cancer
Regular exercise appears to help mitigate the increased cardiovascular risk faced by women treated for breast cancer, according to a study scheduled for presentation at the American College of Cardiology's 66th Annual Scientific Session (ACC.17). The study found that women with breast cancer who...
Key Gene Controlling Tumor Growth in Gliomas Pinpointed
Cedars-Sinai investigators have identified a stem cell–regulating gene that affects tumor growth in patients with brain cancer and can strongly influence survival rates of patients. The findings, published by Edwards et al in Nature Scientific Reports, could move physicians closer to their...
Use of Evidence-Based Prostate Cancer Imaging in an Integrated Health-Care System
In a study reported in the Journal of Oncology Practice, Salloum et al found that use of nonindicated imaging for diagnostic staging of low-risk prostate cancer in a nonprofit integrated health-care system remained common but has decreased in frequency. As noted by the authors: “The overuse...
Dutch Study Examines Effect of Internet-Based Cognitive Behavioral Therapy on Sexual Functioning in Breast Cancer Survivors
In a Dutch study reported in the Journal of Clinical Oncology, Hummel et al found that use of an Internet-based cognitive behavioral therapy intervention improved sexual functioning among breast cancer survivors. Study Details In the study, 169 women with a diagnosis of sexual dysfunction from 10 ...
UK Trial Shows No Survival Benefit in Adding Pravastatin to Standard Chemotherapy in Small Cell Lung Cancer
In the UK phase III LUNGSTAR study reported in the Journal of Clinical Oncology, Seckl et al found that adding pravastatin to first-line standard chemotherapy did not improve overall survival in patients with small cell lung cancer (SCLC). Numerous large prospective cohort and registry studies...
ASCO Urges Lawmakers to Fund Cancer Research on Capitol Hill
The importance of a strong federal investment in cancer research was front and center at ASCO’s congressional briefing this past month, where the Society presented Clinical Cancer Advances 2017: ASCO’s Annual Report on Progress Against Cancer. In addition to announcing the top cancer advance of the ...
Spotlight: ASCO Clinical Affairs
ASCO is working—through research, education, and promotion of the highest quality patient care—toward a world where cancer is prevented or cured, and every survivor is healthy. With the goal of ensuring that all patients receive the high-quality care they expect and deserve, ASCO is committed to...
